SA521420951B1 - مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز - Google Patents

مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز

Info

Publication number
SA521420951B1
SA521420951B1 SA521420951A SA521420951A SA521420951B1 SA 521420951 B1 SA521420951 B1 SA 521420951B1 SA 521420951 A SA521420951 A SA 521420951A SA 521420951 A SA521420951 A SA 521420951A SA 521420951 B1 SA521420951 B1 SA 521420951B1
Authority
SA
Saudi Arabia
Prior art keywords
triazole
carboxylate
methyl
carboxylic acid
methoxybenzyl
Prior art date
Application number
SA521420951A
Other languages
Arabic (ar)
English (en)
Inventor
زافير فيرنانديـز ميجول
اكباريروماني إلهام
ثاكور بالافي
بياوليو مارك-اندري
زامبوني روبرت
ماج هانز
ليبلانك يفيس
Original Assignee
كانتيرو ثيرابيوتكس، انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by كانتيرو ثيرابيوتكس، انك. filed Critical كانتيرو ثيرابيوتكس، انك.
Publication of SA521420951B1 publication Critical patent/SA521420951B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SA521420951A 2018-07-06 2021-01-03 مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز SA521420951B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US201962827573P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
SA521420951B1 true SA521420951B1 (ar) 2024-03-24

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521420951A SA521420951B1 (ar) 2018-07-06 2021-01-03 مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز

Country Status (14)

Country Link
US (2) US11401246B2 (cg-RX-API-DMAC7.html)
EP (1) EP3817816A1 (cg-RX-API-DMAC7.html)
JP (1) JP7348705B2 (cg-RX-API-DMAC7.html)
KR (1) KR102865323B1 (cg-RX-API-DMAC7.html)
CN (1) CN112399873B (cg-RX-API-DMAC7.html)
AU (1) AU2019297523B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000050A2 (cg-RX-API-DMAC7.html)
CO (1) CO2021001277A2 (cg-RX-API-DMAC7.html)
IL (1) IL279952B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000051A (cg-RX-API-DMAC7.html)
PE (1) PE20210859A1 (cg-RX-API-DMAC7.html)
SA (1) SA521420951B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012930RA (cg-RX-API-DMAC7.html)
WO (1) WO2020010309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279952B2 (en) 2018-07-06 2024-11-01 Cantero Therapeutics Inc Triazole glycolate oxidase inhibitors
WO2021086874A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
WO2021142155A1 (en) * 2020-01-08 2021-07-15 Orfan Biotech Inc. Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
TW202339727A (zh) * 2021-10-11 2023-10-16 美商坎特羅治療股份有限公司 使用1h-1,2,3-三唑-4-羧酸之治療方法
WO2024109917A1 (zh) * 2022-11-25 2024-05-30 西藏海思科制药有限公司 一种三唑衍生物及其在医药上的应用
WO2024212137A1 (en) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
US10766829B2 (en) 2015-03-19 2020-09-08 KOHJIN Life Sciences Co., Ltd. Yeast extract having effect of promoting growth of plant and elongation of root and effect of improving added values of plant
EP3386949A4 (en) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2019133813A1 (en) 2017-12-29 2019-07-04 Orfan Biotech Inc. Glycolate oxidase inhibitors and use thereof
WO2019165159A1 (en) 2018-02-23 2019-08-29 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
IL279952B2 (en) 2018-07-06 2024-11-01 Cantero Therapeutics Inc Triazole glycolate oxidase inhibitors
EP3986863A4 (en) 2019-06-19 2023-01-18 BioMarin Pharmaceutical Inc. GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES

Also Published As

Publication number Publication date
JP7348705B2 (ja) 2023-09-21
US20210403439A1 (en) 2021-12-30
JP2021530560A (ja) 2021-11-11
MX2021000051A (es) 2021-03-25
SG11202012930RA (en) 2021-01-28
AU2019297523B2 (en) 2025-04-17
KR102865323B1 (ko) 2025-09-26
WO2020010309A1 (en) 2020-01-09
CN112399873B (zh) 2024-10-25
CA3104529A1 (en) 2020-01-09
IL279952B2 (en) 2024-11-01
KR20210041564A (ko) 2021-04-15
IL279952B1 (en) 2024-07-01
US11401246B2 (en) 2022-08-02
AU2019297523A1 (en) 2021-02-25
US20230143491A1 (en) 2023-05-11
EP3817816A1 (en) 2021-05-12
WO2020010309A9 (en) 2020-01-30
CN112399873A (zh) 2021-02-23
PE20210859A1 (es) 2021-05-18
IL279952A (en) 2021-03-01
CO2021001277A2 (es) 2021-04-30
BR112021000050A2 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
MX2021000051A (es) Inhibidores de triazol glicolato oxidasa.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
PH12021500014A1 (en) Fused ring compounds
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
MX2022006986A (es) Inhibidores de kras g12c.
MY199730A (en) Piperidine-substituted mnk inhibitors and methods related thereto
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
PH12021552482A1 (en) Compounds targeting prmt5
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12020550792A1 (en) Compounds useful for inhibiting cdk7
WO2017109488A8 (en) Cyanopyrrolidine derivatives as inhibitors for dubs
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
MY197116A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
CA3139148A1 (en) Crystalline salt forms of a kinase inhibitor
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EP4691564A3 (en) Neurokinin inhibitors such as aprepitant for treating non small cell lung carcinoma or breast cancer without mutations
IL320582A (en) Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
AU2020378127A8 (en) Compounds as CD73 inhibitors
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same